Compare PulteGroup, Inc. (PHM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs Viatris Inc — how do they compare? PulteGroup, Inc. trades at $112.38 (market cap $21.63B), while Viatris Inc trades at $17.52 (market cap $20.03B). The key difference: PulteGroup, Inc. and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and Viatris Inc for 57 Days on average.
| PHM | VTRS | |
|---|---|---|
Market Cap | $21.63B | $20.03B |
Volume | 2,324,729 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $18.27 |
52-Week Low | $110.11 | $9.74 |
Typical Hold Time | 91 Days | 57 Days |
Enterprise Value | $22.04B | $32.15B |
Dividend Yield | 0.92% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $112.33, down 3.25% amid broader housing sector weakness driven by rising mortgage rates. The stock shows bearish technical signals with key support at $110, while fundamentals reveal solid profitability with 11.62% net margin and attractive valuation at P/E of 11.6. Recent earnings show mixed results with Q2 beat but Q4 and Q1 misses, with Q3 results pending. The company maintains strong cash flow generation with $355M net cash flow in 2025.
PHM presents a value opportunity with below-market valuation and consistent profitability, though near-term headwinds from rising rates pressure housing demand. Analyst consensus targets $139.80 (24% upside) with 45% buy ratings, but technical weakness and macroeconomic risks require careful monitoring. The dividend yield provides income support during market volatility.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
